Indeed, stimulation with TMZ and AT101 resulted in higher cytotoxicity and better tumor growth control of MGMT promoter-methylated, patient-derived, primary GBM cells compared to a single TMZ treatment [17]. The gene discussed is MGMT; the disease is glioblastoma.